26 May 2013
Keywords: methylnaltrexone, nda, sees, 3-month, extension, progenics, pharmaceuticals
Article | 21 January 2008
Progenics Pharmaceuticals and fellow USA-based Wyeth say that the Food and Drug Administration has extended the review of their New ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 January 2008
24 May 2013
© 2013 thepharmaletter.com